(Q57218078)

English

Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease

No description defined

In more languages

edit

Statements

instance of

scholarly article

0 references

title

Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease (English)

0 references

main subject

chronic renal insufficiency

1 reference

Christin Spatz

1

0 references

Kevin Roe

series ordinal

2

0 references

Erik Lehman

series ordinal

3

0 references

Navin Verma

series ordinal

4

0 references

language of work or name

English

0 references

publication date

2013

0 references

published in

Nephron Clinical Practice

0 references

volume

123

0 references

issue

1-2

0 references

page(s)

61-6

0 references

cites work

The emerging role of phosphate in vascular calcification

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1159%2F000351811

retrieved

21 January 2018

Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1159%2F000351811

retrieved

21 January 2018

Relation between serum phosphate level and cardiovascular event rate in people with coronary disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1159%2F000351811

retrieved

21 January 2018

Serum phosphate levels and mortality risk among people with chronic kidney disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1159%2F000351811

retrieved

21 January 2018

Fibroblast growth factor 23: the making of a hormone

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1159%2F000351811

retrieved

21 January 2018

FGF23 is a hormone-regulating phosphate metabolism--unique biological characteristics of FGF23.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1159%2F000351811

retrieved

21 January 2018

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1159%2F000351811

retrieved

21 January 2018

Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1159%2F000351811

retrieved

21 January 2018

Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1159%2F000351811

retrieved

21 January 2018

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1159%2F000351811

retrieved

21 January 2018

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1159%2F000351811

retrieved

21 January 2018

Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1159%2F000351811

retrieved

21 January 2018

Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1159%2F000351811

retrieved

21 January 2018

Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1159%2F000351811

retrieved

21 January 2018

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1159%2F000351811

retrieved

21 January 2018

Effects of dietary phosphate and calcium intake on fibroblast growth factor-23

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1159%2F000351811

retrieved

21 January 2018

Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1159%2F000351811

retrieved

21 January 2018

Effects of phosphate binders in moderate CKD

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1159%2F000351811

retrieved

21 January 2018

Identifiers

DOI

10.1159/000351811

0 references

PubMed publication ID

23774446

0 references

(Q57218078)

Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)